SHILPAMEDShilpa Medicare Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

₹625.45

▲ 0.84%

Strong

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)12,209.20

P/E50.30

P/B4.71

PEG0.08

ROE %9.82

ROCE %11.60

Debt / Equity0.25

EPS12.41

Revenue Growth %31.50

Profit Growth %644.60

Dividend Yield %0.08

Promoter Holding %55.38

FII Holding %10.65

DII Holding %—

Beta0.20

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on SHILPAMED — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

BUYConviction 73%

Why buy

• Revenue growth: 31.5% YoY
• Profit growth: 644.6% YoY
• Debt/Equity: 0.25
• RSI: 61
• Price vs EMA21: above
• Price vs SMA50: above

Bull case

• Revenue growth: 31.5% YoY
• Profit growth: 644.6% YoY
• Debt/Equity: 0.25
• RSI: 61

Bear case

• ROE: 9.8%
• Dividend yield: 0.08%
• MACD: bearish
• Volume: 0.4x 20-day average

Key risks

• ROE: 9.8%
• Dividend yield: 0.08%

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)

₹625.45

Stop Loss

₹566.48

risk 9.4%

Target 1 (1.5R)

₹713.91

+14.1%

Target 2 (3R)

₹802.37

+28.3%

Support (20d)

₹548.20

Resistance (52w)

₹650.00

Risk : Reward

1 : 1.5 → 1 : 3

risking ₹58.97/share

ATR (volatility)

₹23.59

avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹23.59). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental

Technical

Momentum

Risk (safety)

Peers — Pharma

About

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.